Baxter sells its Vero cell technology; Santen, Durect form drug delivery partnership;

> Baxter International ($BAX) entered into a definitive agreement to sell its Vero cell-based technology for vaccine production to Nanotherapeutics. Release

> Santen Pharmaceutical now has exclusive worldwide rights to sell a sustained-release product that uses Durect's saber technology. The terms of an agreement between the two companies calls for Santen to pay Durect a fee of $2 million. Story